Juno And Other Gene Therapy Players Are Hot Despite Ongoing Pricing Debates

The rumored acquisition of CAR-T developer Juno by Celgene has ignited investor enthusiasm for gene therapy. But in the background, concerns about how the healthcare system will afford these pricey new treatments persist.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Tags: NASDAQ:JUNO Source Type: news